The Alopecia Areata Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Alopecia Areata Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alopecia Areata Market.
Some of the key takeaways from the Alopecia Areata Pipeline Report:
Companies across the globe are diligently working toward developing novel Alopecia Areata treatment therapies with a considerable amount of success over the years.
Alopecia Areata companies working in the treatment market are Concert Pharmaceutical, Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, Chipscreen Biosciences, Forte Biosciences, HCW Biologics, Reistone Biopharma Company, Suzhou Zelgen Biopharmaceuticals, and others, are developing therapies for the Alopecia Areata treatment
Emerging Alopecia Areata therapies in the different phases of clinical trials are- CS 12192, FB-102, HCW 9302, ANB030, LP-0133, LH-8, SHR0302, Jaktinib, CTP-543, and others are expected to have a significant impact on the Alopecia Areata market in the coming years.
In October 2023, Inmagene Biopharmaceuticals has begun dosing the first subject in a Phase IIa trial of IMG-007, an anti-OX40 monoclonal antibody (mAb) with an extended half-life, for the treatment of alopecia areata (AA). This global multicenter trial will evaluate the efficacy, safety, biomarkers, and pharmacokinetics of IMG-007 in AA patients with 50% or greater scalp hair loss. The humanized IgG1 mAb specifically targets the OX40 receptor and is designed to effectively block the signaling between OX40 and its ligand.
In June 2023, The FDA has approved ritlecitinib, a Janus kinase (JAK) inhibitor, for the treatment of alopecia areata in adolescents and adults. Marketed under the name Litfulo, this oral medication offers a new option for patients with the condition.
Alopecia Areata Overview
Alopecia areata is an autoimmune disorder characterized by unpredictable, patchy hair loss on the scalp, face, or other areas of the body. It occurs when the body’s immune system mistakenly attacks hair follicles, leading to hair loss. The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune factors.
Get a Free Sample PDF Report to know more about Alopecia Areata Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight
Emerging Alopecia Areata Drugs Under Different Phases of Clinical Development Include:
CS 12192: Chipscreen Biosciences
FB-102: Forte Biosciences
HCW 9302: HCW Biologics
Deuruxolitinib: Concert Pharmaceuticals
EQ101: Equillium
MAX 40070: Maxinovel Pharmaceuticals
ANB030: AnaptysBio
LP-0133: LEO Pharma
LH-8: Legacy Healthcare
SHR0302: Reistone Biopharma Company
Jaktinib: Suzhou Zelgen Biopharmaceuticals
CTP-543: Concert Pharmaceutical
Route of Administration
Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Alopecia Areata Pipeline Therapeutics Assessment
Alopecia Areata Assessment by Product Type
Alopecia Areata By Stage and Product Type
Alopecia Areata Assessment by Route of Administration
Alopecia Areata By Stage and Route of Administration
Alopecia Areata Assessment by Molecule Type
Alopecia Areata by Stage and Molecule Type
DelveInsight’s Alopecia Areata Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Alopecia Areata product details are provided in the report. Download the Alopecia Areata pipeline report to learn more about the emerging Alopecia Areata therapies
Some of the key companies in the Alopecia Areata Therapeutics Market include:
Key companies developing therapies for Alopecia Areata are – Aclaris Therapeutics, Concert Pharmaceuticals, Pfizer, Bristol Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Galderma, Regeneron Pharmaceuticals, Kythera Biopharmaceuticals, Cipla Ltd., Histogen, Allergan, Cassiopea S.p.A., Berg LLC, Follica, Inc., Stemson Therapeutics, RepliCel Life Sciences Inc., Kyocera Corporation, and others.
Alopecia Areata Pipeline Analysis:
The Alopecia Areata pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
Alopecia Areata key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alopecia Areata drugs and therapies
Alopecia Areata Pipeline Market Drivers
Increasing in the number of cases of alopecia areata, increasing Research and Development activities in Alopecia treatment are some of the important factors that are fueling the Alopecia Areata Market.
Alopecia Areata Pipeline Market Barriers
However, lack of approved therapies to treat alopecia Areata, side effects associated with the current treatment options and other factors are creating obstacles in the Alopecia Areata Market growth.
Scope of Alopecia Areata Pipeline Drug Insight
Coverage: Global
Key Alopecia Areata Companies: Concert Pharmaceutical, Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, Chipscreen Biosciences, Forte Biosciences, HCW Biologics, Reistone Biopharma Company, Suzhou Zelgen Biopharmaceuticals, and others
Key Alopecia Areata Therapies: CS 12192, FB-102, HCW 9302, ANB030, LP-0133, LH-8, SHR0302, Jaktinib, CTP-543, and others
Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers
Request for Sample PDF Report for Alopecia Areata Pipeline Assessment and clinical trials
Table of Contents
1
Alopecia Areata Report Introduction
2
Alopecia Areata Executive Summary
3
Alopecia Areata Overview
4
Alopecia Areata- Analytical Perspective In-depth Commercial Assessment
5
Alopecia Areata Pipeline Therapeutics
6
Alopecia Areata Late Stage Products (Phase II/III)
7
Alopecia Areata Mid Stage Products (Phase II)
8
Alopecia Areata Early Stage Products (Phase I)
9
Alopecia Areata Preclinical Stage Products
10
Alopecia Areata Therapeutics Assessment
11
Alopecia Areata Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Alopecia Areata Key Companies
14
Alopecia Areata Key Products
15
Alopecia Areata Unmet Needs
16
Alopecia Areata Market Drivers and Barriers
17
Alopecia Areata Future Perspectives and Conclusion
18
Alopecia Areata Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
